Biossil
AI-native biopharma company advancing 11 Phase 2 & 3 programs across life-threatening diseases using synthetic biology and metabolic engineering.
Private Company
Funding information not available
AI Company Overview
AI-native biopharma company advancing 11 Phase 2 & 3 programs across life-threatening diseases using synthetic biology and metabolic engineering.
Technology Platform
AI-native drug discovery platform integrated with synthetic biology and metabolic engineering, leveraging machine learning for target identification and therapeutic design.
Opportunities
Risk Factors
Competitive Landscape
Competes with both traditional biopharma companies in specific indications and AI-driven drug discovery platforms like Recursion, Exscientia, and Insilico Medicine, differentiating through synthetic biology integration and unusually rapid clinical progression.